Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
Restaurants get off to a quick start thanks to game-changing policies
High service charges on event ticket refunds call for further regulation
Sunday
- Subscribe
Pharma firms fined for price monopoly
Print Edition
CHINA’S top economic planner said yesterday that two domestic medicine firms had been fined for monopoly pricing practices.
Zhejiang Second Pharma and Tianjin Handewei Pharmaceutical were fined a total of 443,900 yuan (US$65,975) for fixing prices for an active pharmaceutical ingredient, said a National Development and Reform Commission statement.
The two companies charged an unfairly high price for Isoniazid, an antibiotic used to treat tuberculosis, and declined sales with no justified cause, the statement said.
The two companies have since restored regular pricing and revived market competition.
Monopoly practices in the pharmaceutical sector have been a focus of China’s anti-monopoly supervision for some time. The case will help regulate active pharmaceutical ingredient pricing and ensure a fair environment for medicine purchases and sales, according to the NDRC.
The NDRC has vowed to increase anti-monopoly supervision.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
